BridgeBio Pharma, Inc. (BBIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
BridgeBio's quarterly revenue has accelerated from $2.2M in 2024Q2 to $353.2M in 2026Q3, with the latest quarter growing 192.6% year over year, suggesting a commercial inflection concentrated in the Attruby launch.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has been sharp, with the 2026Q3 operating margin narrowing to -3.3% from -120.1% in 2025Q4 and gross margins holding near 94.2%, though net losses of $56.7M persist.
Interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 met efficacy endpoints, indicating strong clinical progress.
BridgeBio Pharma's Attruby has shown a strong U.S. launch, contributing to favorable competitive dynamics and revenue growth.
Analysts maintain a Buy rating on BBIO, citing strong clinical and commercial performance as key drivers.
Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | -$0.42+22.5% vs -$0.54 | $353M+20.3% vs $293M |
Q3 2026 Aug 10, 2026 | -$0.78-35.5% vs -$0.58 | $244M+10.3% vs $221M |
Q2 2026 May 7, 2026 | -$0.84-23.8% vs -$0.68 | $195M+9.2% vs $178M |
Q1 2026 Feb 24, 2026 | -$1.00-40.2% vs -$0.71 | $154M+5.0% vs $147M |
BridgeBio Pharma, Inc. (BBIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of NVIDIA Corporation (NASDAQ: NVDA). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in NVIDIA stock on October 20th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account. Representative Gilbert Ray
PALO ALTO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced 28 abstracts on acoramidis in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) comprised of 12 new posters, seven encore poster presentations, and nine encore posters, will be shared at the XX International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18, 2026, in Montevideo, Uruguay. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.
PALO ALTO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:
Benchmark BBIO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BridgeBio Pharma, Inc. (BBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $77.36 | $15.15B | -26.60 | 126.26% | -60.3% | — | — | |
| $125.85 | $10.35B | -36.05 | -16.72% | -341.87% | -22.39% | — | |
| $4.67 | $718.37M | -6.47 | 40.22% | -9.91% | -39.51% | — | |
| $16.86 | $2.12B | -4.83 | -4.26% | -445% | -90.04% | — | |
| $310.27 | $8.65B | -25.19 | -100% | — | -29.41% | — | |
| $537.79 | $136.49B | 34.52 | 9.57% | 30.61% | 20.08% | — |
BridgeBio Pharma, Inc. (BBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BridgeBio Pharma, Inc. (BBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Oct 13, 2026·SEC
Aug 17, 2026·SEC
Get notified when BBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BridgeBio Pharma, Inc. (BBIO) stock FAQ — growth, dividends, profitability & financials explained
BridgeBio Pharma, Inc. (BBIO) reported $945.5M in revenue over the trailing twelve months. Revenue was $502.1M in fiscal year 2025.
BridgeBio Pharma, Inc. (BBIO) grew revenue by 167.3% over the trailing twelve months, compared with the twelve months before.
No. BridgeBio Pharma, Inc. (BBIO) reported a net loss of $570.2M over the trailing twelve months.
BridgeBio Pharma, Inc. (BBIO) had negative free cash flow of $374.3M over the trailing twelve months.